Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Barrie D. Evans"'
Autor:
V J Harvey, Anne Lethaby, Vijay Singh, Paul Thompson, Barbara H. Mason, Ian M. Holdaway, Barrie D. Evans
Publikováno v:
ANZ Journal of Surgery. 73:905-908
Background: Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3) appear to influence the growth of breast cancer cells in vitro, and epidemiological studies suggest higher serum IGF-I levels increase the risk of breast cancer. IGF
Autor:
Paul Thompson, Michael R. McCrystal, David Porter, Bruce C. Baguley, V J Harvey, Barrie D. Evans
Publikováno v:
Cancer Chemotherapy and Pharmacology. 44:39-44
N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (DACA) is a new DNA-intercalating drug with a dual mode of cytotoxic action that is thought to involve topoisomerases I and II. On the basis of novelty of action and promising preclinical activity agai
Autor:
James W. Paxton, Philip Kestell, Michael R. McCrystal, Bruce C. Baguley, Ranjith S.K.A. Gamage, Barrie D. Evans, Ingrid C. Dunlop
Publikováno v:
Cancer Chemotherapy and Pharmacology. 44:45-50
DACA [N-[2-(dimethylamino)ethyl]acridine-4-carboxamide] is an acridine derivative with high activity against solid tumours in mice and a dual mode of cytotoxic action involving topoisomerases I and II. The plasma pharmacokinetics of DACA were studied
Autor:
Ian M, Holdaway, Barbara H, Mason, Anne E, Lethaby, Vijay, Singh, Vernon J, Harvey, Paul I, Thompson, Barrie D, Evans
Publikováno v:
ANZ journal of surgery. 73(11)
Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3) appear to influence the growth of breast cancer cells in vitro, and epidemiological studies suggest higher serum IGF-I levels increase the risk of breast cancer. IGF-I and IGFBP
Autor:
Michael R. McCrystal, James W. Paxton, Iain G. C. Robertson, Philip C. Schofield, Philip Kestell, Barrie D. Evans, Bruce C. Baguley
Publikováno v:
Cancer chemotherapy and pharmacology. 44(1)
N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (DACA) is an experimental antitumour agent that has just completed phase I clinical trials in New Zealand and the United Kingdom. Urine (0–72 h) was analysed from 20 patients receiving DACA infused o
Autor:
Paul Mitchell, Carol Stone, Patricia Melville, Dora Mak, Paul Thompson, Barrie D. Evans, Christopher Ellis, Vernon Harvey
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 1(4)
At Auckland hospital there is a combined medical and nursing preparation for patients receiving cytotoxic chemotherapy. The aim of the current study was to assess whether patients felt that this combined approach had prepared them adequately for chem
Publikováno v:
Cancer treatment reviews. 10
Twenty-seven patients, 16 with limited disease and 11 with extensive disease have so far been entered into the study. Conventional chemotherapy consisted of VP-16 100 mg/m 2 i.v. days I-3, adriamycin 40 mg/m 2 day 1 and vincristine 1.4 mg/m 2 day 1 (
Publikováno v:
Cancer chemotherapy and pharmacology. 21(1)
Response to second-line therapy in relapsing patients with small cell lung carcinoma (SCLC) is often claimed to be evidence in favour of non-cross resistance. Fifteen patients with SCLC who had relapsed off treatment after responding to initial first
Autor:
Ian E. Smith, Barrie D. Evans
Publikováno v:
Cancer treatment reviews. 12
Carboplatin, a cisplatin analogue without significant nephrotoxicity, was used as a single agent in the treatment of 56 patients with small cell lung carcinoma at a dose of 300–400 mg/m 2 i.v. monthly. Twenty-three patients (41%) achieved a respons
Autor:
Faroughi Niya, Homayoun1 (AUTHOR), Fatahpour, Maryam1 (AUTHOR), Hazeri, Nourallah1 (AUTHOR) nhazeri@chem.usb.ac.ir
Publikováno v:
Polycyclic Aromatic Compounds. 2020, Vol. 40 Issue 3, p774-783. 10p.